Strychnine – A Killer from the Past

Igor Makarovsky MSc1, Gal Markel MD PhD1,2, Azik Hoffman MD1, Ophir Schein MD1, Tal Brosh-Nissimov MD1, Zeev Tashma PhD1,3, Tsvika Dushnitsky MD1 and Arik Eisenkraft MD1

1CBRN Medicine Branch, Medical Corps, Israel Defense Force
2Sheba Cancer Research Center, Sheba Medical Center, Tel Hashomer, Israel
3Department of Medicinal Chemistry and Natural Products, School of Pharmacy, Hebrew University-Hadassah Medical School, Jerusalem, Israel

Key words: strychnine, terror, glycine antagonist, convulsions, health effects, medical care

Strychnine is a natural alkaloid commercially obtained from the dried seeds of Strychnos nux-vomica. The various species of Strychnos, distributed around the world’s tropics, include Strychnos nux-vomica, a tree native to southeast Asia, especially India and Myanmar (formerly Burma); Strychnos toxifera, a plant source of the poison curare, originating from South America; Strychnos spinosa, found mainly in tropical and subtropical Africa (the species was recently introduced into Israel as a potential new commercial crop); and Strychnos potatorum, found in India and used as a coagulant to purify water [1]. Seeds of Strychnos nux-vomica contain 1.1–1.4% strychnine [2]. Commercial baits, usually containing < 0.5% strychnine by weight, are pelleted and often dyed red or green. It is highly toxic to humans and most domestic animals and is used mainly as a rodenticide.

Over the years the cancellation of registrations of agents containing strychnine has reduced its usage throughout the world [3]. Israeli authorities have prohibited its use, as have Britain and the European Union, yet it is still in use in other Middle Eastern countries. Veterinarians are allowed to employ it under specific circumstances, e.g., to prevent the spread of rabies.

In the last 20 years human poisonings occurred mainly due to ingestion of the poison in suicidal and homicidal attempts. The lethal dose for human adults ranges between 30 and 120 mg, although death of an adult has been reported after an ingestion of 16 mg. The lethal dose for children is about 15 mg [4,5]. Though strychnine is lethal to humans, early aggressive treatment can be life saving, even following exposure to large doses as high as 3750 mg [6]. In view of the rise in global terrorism, it is important to recognize that strychnine may be utilized by terrorists to induce mass poisoning in urban populations by contamination of major food and water supplies.

This short review focuses on the unique clinical effects of strychnine and the proposed medical care that should be employed in case of strychnine poisoning.

Chemical properties and mechanism of action

Strychnine is a colorless, odorless, bitter-tasting chemical that turns into powder in dry air. The chemical structure of strychnine is illustrated in Figure 1. Strychnine dissolves in acidic media but dissolves poorly in either water or ether [7]. The chemical has a very low vapor pressure and decomposes to release toxic combustion products, such as carbon monoxide, carbon dioxide and various nitrogen oxides [8].

Strychnine interferes with post-synaptic inhibition mediated by glycine, especially in the ventral horns of the spinal cord, brainstem and higher centers. It blocks recurrent inhibition at the Renshaw cell-motor neuron synapse* by competitively antagonizing the action of glycine released by these cells [9-11]. The loss of post-synaptic inhibition results in excessive motor neuron activity and convulsions [9,10]. Central nervous system involvement may also bring about exaggerated responses to visual, auditory and tactile stimulation. Even the slightest breeze may evoke a new set of convulsions [2,12,13].

Pharmacological properties

Strychnine is absorbed very rapidly through the gastrointestinal tract, the respiratory tract and intact skin [14,15]. In addition, it is well absorbed when given via the parenteral route (subcutaneous or intranasal). The first symptoms usually appear within 5 minutes to 1 hour after exposure, depending on the dose, the route of exposure, and the general medical health of the person exposed. It undergoes rapid and extensive metabolism by hepatic cytochrome P-450 2B and it does not seem to have an accumulative effect [2,5]. Five metabolites formed in vitro by rabbit liver were isolated and purified. Three of them were identified as 2-hydroxystrychnine, 2,3-dihydroxystrychnine, and 2,3-dihydroxystrychnine.

* Renshaw cells are interneurons in the ventromedial region of the ventral horn that make inhibitory connections with the motoneurons.
strychnine N-oxide, and 21α,22β-dihydroxy-22-hydroxystrychnine, when compared to authentic samples by means of ultraviolet, nuclear magnetic resonance and mass spectrometries. Additionally, two other metabolites were tentatively identified as strychnine by spectral measurements: 21,22-epoxide and 11,12-dehydrostrychnine. Strychnine N-oxide was the major metabolite and accounted for approximately 15% of the metabolized strychnine. All other metabolites accounted for < 1% [16].

The combination of detoxification and excretion renders strychnine a biological half-life (in humans) of 10–12 hours [2,17]. Up to 20% is excreted unchanged in the urine within 24 hours [2].

**Health effects**

Most strychnine poisonings occur through ingestion or inhalation, while only a few cases are due to topical exposure. Clinical manifestations begin with a prodromal stage.

**Prodromal stage**

Prodromal symptoms may often occur within 15–30 minutes following ingestion or 5 minutes after inhalation. In case of a topical exposure, the prodromal period may last up to 14–15 hours [14]. These symptoms include apprehension, restlessness, a heightened sense of awareness (hearing, vision, tactile sensation, etc.), hyper-reflexia and muscular stiffness of face and legs. Vomiting is uncommon [2].

**Clinical stage**

The clinical hallmark of this stage is manifested mainly by recurrent violent seizures while the victim is fully alert [2,12]. Short yet violent convulsions lasting from 30 seconds to 2 minutes are triggered even by a faint sensory stimulus. The combination of convulsions with intact sensorium is the most noticeable manifestation of strychnine poisoning. These convulsions are clonic at first, and then become tetanic with opisthotonus, trismus of the jaws, and the appearance of “risus sardonicus” (a grinning expression produced by spasm of the facial muscles). The eyes protrude in a fixed stare. Tetanic contractions of the diaphragm, thoracic muscles and abdominal muscles prevent normal respiration, generating anoxia and cyanosis. The convulsions may be accompanied by mydriasis, proptosis, and conjugated or dissociated deviations of the eyes. Full consciousness is present throughout the seizure and the victim remains anxious, frightened and in pain. Complete muscular relaxation occurs between the convulsions, while only a few cases are due to topical exposure. Clinical manifestations begin with a prodromal stage.

**Table 1. Major human health effects following strychnine poisoning**

<table>
<thead>
<tr>
<th>System</th>
<th>Prodromal stage</th>
<th>Clinical stage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eyes</td>
<td>Vomiting (uncommon)</td>
<td>Vomiting</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>Weak pulse, tachycardia, hypertension, cardiac arrest</td>
<td></td>
</tr>
<tr>
<td>Renal and urinary tract</td>
<td>Myoglobinuria, acute renal failure</td>
<td></td>
</tr>
<tr>
<td>Musculoskeletal and smooth muscles</td>
<td>Stiffness of facial and neck muscles, hyper-reflexia</td>
<td>Contractions of all voluntary muscles simultaneously, including chest and abdominal muscles, hypertonicity of the muscles, tonic twitching of the face and neck muscles, trismus, risus sardonicus, rhabdomyolysis</td>
</tr>
<tr>
<td>Metabolic</td>
<td>Hyperthermia</td>
<td></td>
</tr>
<tr>
<td>Laboratory findings</td>
<td>Lactic acidosis, hyperkalemia, elevations of AST, LDH, CPK, leukocytosis</td>
<td></td>
</tr>
<tr>
<td>Carcinogenicity</td>
<td>Not considered a carcinogen</td>
<td></td>
</tr>
</tbody>
</table>

**Differential diagnosis**

Strychnine is a strong convulsing agent. The differential diagnosis includes pathological conditions such as epilepsy, tetanus, meningitis, rabies, phenothiazine overdose, cocaine and phenytoin use, and exposure to chlorinated hydrocarbons, isoniazid, cyanides, organophosphates or other substances that may cause myoclonus or seizures [3,12]. The victim, however, remains conscious until moments before death, which distinguishes this condition from various causes and forms of epilepsy. The absence of fever and the sudden onset of convulsions exclude meningitis and meningoencephalitis. The relatively clear sensorium, coupled with powerful and painful convulsions, arouses panic in the patient [12,13,17].

**Medical care**

In severe cases of strychnine intoxication the patient dies before reaching the hospital. Since strychnine does not have a specific antidote, the treatment is supportive and symptomatic. The pa-
tient should be moved to a dark and quiet room, and vomiting should not be induced since it may lead to asphyxia.

The spasmodic motoneuron activity is generally treated with intravenous benzodiazepines (e.g., diazepam or midazolam) or a short-acting barbiturate [15,18,19]. When unsuccessful, the patient should be sedated and paralyzed, usually with neuromuscular blockers such as pancuronium or vecuronium bromide, then ventilated [20,21]. Introducing a nasogastric tube may trigger a new attack and should be avoided if possible. Strychnine is rapidly absorbed and by the time the patient arrives at the emergency department it is unlikely to be found in the stomach. This renders gastrointestinal decontamination useless.

Hyperthermia should be treated aggressively by active cooling with ice-water immersion, cooling blanket or cool mist, depending on the degree of temperature elevation [12,18]. In severe cases of hyperthermia dantrolene may be used.

Rhabdomyolysis, metabolic acidosis and myoglobinuria may occur secondary to severe muscular spasms during seizures. It is important to monitor the patient and correct these conditions in time [21]. Levels of lactate dehydrogenase, creatine phosphokinase, aspartate aminotransferase, urine myoglobin and coagulation should be monitored for 24–48 hours. Urine output should be promoted. Strychnine levels may be detected in the blood, urine or other organs, but these do not correlate well with clinical toxicity or the need for therapy [22]. A biopsy reported by Perper [23] identified strychnine in the gastrointestinal tract, in the kidneys and urine, in the plasma, and a small amount was even detected in the cerebrospinal fluid. Usually, if the victim survives the critical phase (first 24 hours), even after ingesting a large dose of strychnine, the prognosis is favorable, with an average treatment time of a few days to a few weeks until full recovery [13,24].

Case studies
Although strychnine is now used only as a rodenticide and occasionally to eradicate rabies, some use it for other purposes. There are three major causes of strychnine intoxication: suicide attempts, accidental ingestion (especially by children, since strychnine tablets may look like pink or green candies), or as an adulterant in street drugs (such as amphetamines, heroin and cocaine) [20].

It has also been used with intent to kill. The only mass-poisoning event with strychnine that we found occurred about 150 years ago in the “new world.” While celebrating a peace agreement with the Shasta nation (an Indian tribe in early California) at Fort Jones in 1851, the Americans fed the Indians meat laced with strychnine. As a result, 4000 Indians died from poisoning [25]. Representative contemporary strychnine poisoning cases are listed in Table 2.

---

**Table 2. Representative contemporary strychnine poisoning cases**

<table>
<thead>
<tr>
<th>Year and place</th>
<th>Case 1</th>
<th>Case 2</th>
<th>Case 3</th>
<th>Case 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Publication</td>
<td>Perper</td>
<td>Tamarick et al.</td>
<td>Greene &amp; Meatherall</td>
<td>Starretz-Hacham et al.</td>
</tr>
<tr>
<td>Age</td>
<td>56</td>
<td>14</td>
<td>50</td>
<td>6</td>
</tr>
<tr>
<td>Gender</td>
<td>Male</td>
<td>Female</td>
<td>Female</td>
<td>Male</td>
</tr>
<tr>
<td>Intention</td>
<td>Suicidal</td>
<td>Innocent</td>
<td>Innocent</td>
<td>Innocent</td>
</tr>
<tr>
<td>Source</td>
<td>76 g of “Mole-Nets” rodenticide containing 0.35% of strychnine sulfate</td>
<td>A suspected bottle of medication</td>
<td>An old bottle of strychnine solution</td>
<td>Several pink tablets of unknown substance (approximately 140 mg strychnine)</td>
</tr>
<tr>
<td>Route</td>
<td>Ingestion</td>
<td>Intravenous</td>
<td>Dermal</td>
<td>Ingestion</td>
</tr>
<tr>
<td>Time to onset</td>
<td>50 min</td>
<td>30 min</td>
<td>14–15 hrs</td>
<td>30 min</td>
</tr>
<tr>
<td>Clinical manifestations</td>
<td>Full consciousness, abdominal pains, a set of two 30 sec attacks of tonic convulsions, extreme body rigidity, opisthotonos, a period of total flaccidity, apnea, loss of consciousness</td>
<td>Tonic convulsions, a temperature rise after 24 hrs (40.9°C), diaphoresis, aleteness, inability to walk, loss of feeling in her legs, frequent tonic-clonic convulsions (each lasting for 1–2 minutes) triggered by the slightest stimuli, both feet were drawn up and inward, ECG revealed sinus tachycardia with non-specific ST-T segment abnormalities, myalgia, rhabdomyolysis</td>
<td>Spasms in arms and legs, aleteness, awareness, muscular cramps, pain while opening the jaw, palpation of the calves was painful, dermal hypersensitivity of the legs, could not walk due to pain felt with any attempt to stand</td>
<td>Severe muscle cramps, consciousness yet disorientation, vomiting, severe muscle tetania, mydriasis, hypotension, sinus tachycardia, metabolic acidosis, rhabdomyolysis (CPK 4992 U/L, high serum myoglobin 750 ng/ml, creatinine 1.3 mg/dl)</td>
</tr>
<tr>
<td>Treatment</td>
<td>Cardiopulmonary resuscitation was initiated</td>
<td>Repeated doses of i.v. diazepam 5 mg, sodium bicarbonate 250 ml to correct her acidosis, activated charcoal 30 g per os, adequate hydration and urine output were maintained</td>
<td>Fluid rehydration and alkalinization drugs as prophylaxis against renal failure secondary to rhabdomyolysis (creatinine kinase 677 U/L)</td>
<td>Repeated doses of i.v. diazepam 0.5 mg/kg/dose with no effect, intubation, ventilation, treatment with intravenous vecuronium bromide (0.1 mg/kg/hr for 20 hrs)</td>
</tr>
<tr>
<td>Outcome</td>
<td>Death</td>
<td>Full recovery and discharge after 72 hrs</td>
<td>Condition resolved, discharged 48 hrs after admission, asymptomatic</td>
<td>Good response to medication, discharged after 3 days</td>
</tr>
</tbody>
</table>

---

See refs. 14,21,23,31
Summary
Strychnine is still used as a powerful rodenticide and to a lesser extent against rabies-infected dogs. Strychnine poisoning is characterized by a short prodromal phase, after which there is an unusual combination of seizures with intact sensorium. Complications consist of hyperthermia, renal failure and rhabdomyolysis. The common cause of death is respiratory failure. The most important medical treatment includes termination of seizures (e.g., benzodiazepines), correcting the acidosis, and sedating, paralyzing and ventilating the patient as needed. When dealing with recurrent or unresponsive seizures, the physician should take strychnine poisoning into consideration. Early intervention could save patients’ lives.

References

Correspondence: Dr. A. Eisenkraft, 2 Hatavor Street, Ganei Tikva 55900, Israel.
Phone: (972-3) 737-3108, Fax: (972-3) 737-6111
email: aizenkra@gmail.com

Capsule
Amateur boxing and risk of chronic traumatic brain injury
Loosemore and team retrospectively evaluated the risk of chronic traumatic brain injury from amateur boxing. They found 36 papers with relevant extractable data (from a detailed evaluation of 93 studies of 943 identified from the initial search). The quality of evidence was generally poor. The best quality studies were those with a cohort design and those that used psychometric tests. These yielded the most negative results: only 4 of 17 (24%) better quality studies found any indication of chronic traumatic brain injury in a minority of boxers studied. The authors conclude that there is no strong evidence to associate chronic traumatic brain injury with amateur boxing.